首页> 美国卫生研究院文献>Acta Neuropathologica Communications >Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans
【2h】

Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans

机译:靶向微管结合域的治疗性抗体可通过掩盖神经元表面蛋白聚糖来防止胞外tau蛋白的神经内在化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pathologically altered tau protein is a common denominator of neurodegenerative disorders including Alzheimer’s disease (AD) and other tauopathies. Therefore, promising immunotherapeutic approaches target and eliminate extracellular pathogenic tau species, which are thought to be responsible for seeding and propagation of tau pathology. Tau isoforms in misfolded states can propagate disease pathology in a template-dependent manner, proposed to be mediated by the release and internalization of extracellular tau. Monoclonal antibody DC8E8, binding four highly homologous and independent epitopes in microtubule-binding domain (MTBD) of diseased tau, inhibits tau-tau interaction, discriminates between healthy and pathologically truncated tau and reduces tau pathology in animal model in vivo. Here, we show that DC8E8 antibody acts via extracellular mechanism and does not influence viability and physiological functions of neurons. Importantly, in vitro functional assays showed that DC8E8 recognises pathogenic tau proteins of different size and origin, and potently blocks their entry into neurons. Next, we examined the mechanisms by which mouse antibody DC8E8 and its humanized version AX004 effectively block the neuronal internalization of extracellular AD tau species. We determined a novel mode of action of a therapeutic candidate antibody, which potently inhibits neuronal internalization of AD tau species by masking of epitopes present in MTBD important for interaction with neuron surface Heparan Sulfate Proteoglycans (HSPGs). We show that interference of tau-heparane sulfate interaction with DC8E8 antibody via steric hindrance represents an efficient and important therapeutic approach halting tau propagation.Electronic supplementary materialThe online version of this article (10.1186/s40478-019-0770-y) contains supplementary material, which is available to authorized users.
机译:病理改变的tau蛋白是神经退行性疾病(包括阿尔茨海默氏病(AD)和其他tauopathies)的共同特征。因此,有希望的免疫治疗方法靶向并消除细胞外致病性tau物种,后者被认为是tau病理的播种和繁殖的原因。错折叠状态的Tau同工型可以模板依赖性的方式传播疾病病理,据推测是由细胞外tau的释放和内在介导的。单克隆抗体DC8E8在患病的tau的微管结合域(MTBD)中结合四个高度同源且独立的表位,可抑制tau-tau相互作用,区分健康的tau和病理上被截断的tau,并在体内动物模型中降低tau病理。在这里,我们显示DC8E8抗体通过细胞外机制起作用,并且不影响神经元的活力和生理功能。重要的是,体外功能测定表明DC8E8识别大小和来源不同的致病性tau蛋白,并有力地阻止了它们进入神经元。接下来,我们研究了小鼠抗体DC8E8及其人源化版本AX004有效阻断细胞外AD tau物种神经元内在化的机制。我们确定了一种新型的治疗性候选抗体作用方式,该方式可通过掩盖MTBD中存在的与神经元表面乙酰肝素硫酸蛋白多糖(HSPGs)相互作用重要的表位来有效抑制AD tau物种的神经元内在化。我们证明tau-硫酸乙酰肝素通过空间位阻与DC8E8抗体的相互作用代表了一种有效且重要的治疗方法,可阻止tau的传播。电子补充材料本文的在线版本(10.1186 / s40478-019-0770-y)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号